188 filings
Page 6 of 10
6-K
ydwquwer
30 Jan 19
AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease
6:00am
6-K
t34gv18 ny
23 Jan 19
Current report (foreign)
6:36am
6-K
iykvxe5iwbu0o6970zi
3 Jan 19
AC Immune Announces Appointment of
6:22am
6-K
sxcllykd36 w85630
12 Dec 18
AC Immune and Lilly Announce License and Collaboration Agreement
6:04am
6-K
kcuotaz
7 Dec 18
Current report (foreign)
4:28pm
6-K
a61ppbs
13 Nov 18
Current report (foreign)
6:05am
6-K
q9267oc8 jog
26 Oct 18
Current report (foreign)
5:01pm
6-K
8u1z64
22 Oct 18
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
6:59am
EFFECT
3eem8
7 Sep 18
Notice of effectiveness
12:00am
CORRESP
tyuud5j4 g8m
5 Sep 18
Correspondence with SEC
12:00am
UPLOAD
j8mn8ov 3by5eqn
29 Aug 18
Letter from SEC
12:00am
F-3
r9nr90 cnlrjsnncul
24 Aug 18
Shelf registration (foreign)
12:00am
6-K
gjf 0py2h3
8 Aug 18
Current report (foreign)
6:01am
6-K
9ml2em8 ubahm6s15qq
31 Jul 18
Current report (foreign)
5:04pm
6-K
y3mhpmp6yc90tkjxa
23 Jul 18
Current report (foreign)
4:06pm
424B5
hjrnj6fslrzxb
20 Jul 18
Prospectus supplement for primary offering
6:03am
424B5
km440rrkfgaz0r
19 Jul 18
Prospectus supplement for primary offering
4:17pm
424B5
x4y57t2co
17 Jul 18
Prospectus supplement for primary offering
4:08pm
6-K
pgn5nq9o42ftwk0h a8a
17 Jul 18
Updates on AC Immune’s Pipeline and Technology Platforms to be presented at the Alzheimer’s Association International Conference in Chicago
6:00am
6-K
acfuohb96
6 Jul 18
Current report (foreign)
4:37pm